• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sean Whooley

ACG launches NTone, TSafe range of capsules

March 25, 2021 By Sean Whooley

ACGcaps NTone and TSafe

ACG announced today that it launched its new ACGcaps NTone and ACGcaps TSafe range of capsules for the nutraceutical market. Mumbai, India-based ACG’s NTone portfolio includes naturally colored capsules with no e-number. THe colors used are safe and non-toxic and contain no artificial ingredients, while the product shelf life is unchanged compared to synthetic-colored capsules, […]

Filed Under: Featured, Pharmaceuticals Tagged With: ACG

J&J Vision wins Japanese approval for first drug-releasing contact lens

March 25, 2021 By Sean Whooley

Johnson & Johnson Vision Acuvue Theravision

Johnson & Johnson Vision announced that it received approval in Japan for its Acuvue Theravision lens with Ketotifen. The company touts the lens as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery, according to a news release. Japan’s Ministry of Health, Labour and Welfare (MHLW) approved the lens, […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Regulatory/Compliance Tagged With: Johnson & Johnson

Eyenovia partners with Eversana to commercialize pupil dilation agent

March 23, 2021 By Sean Whooley

Eyenovia Eversana

Eyenovia (NSDQ:EYEN) announced today that it partnered with Eversana to help commercialize MydCombi if it earns U.S. approval. MydCombi is a fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing in an effort to improve the patient experience. The FDA earlier this month accepted Eyenovia’s New Drug […]

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Eversana, Eyenovia Inc.

Research indicates notable future growth in transdermal patch market

March 23, 2021 By Sean Whooley

adhesive microneedle coin-sized insulin patch UCLA diabetes

Research published today has highlighted potential growth down the line in the transdermal drug delivery patch space. Kuick Research published an analysis claiming that the U.S. transdermal patch drug market is revolving on account of two powerful “mega-trends.” Those trends — acceleration in the U.S. pharmaceutical market growth and the restructuring of the healthcare sector […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured Tagged With: Drug delivery

Fractyl enrolls first patient in Revita DMR treatment for Type 2 diabetes

March 22, 2021 By Sean Whooley

Fractyl

Fractyl Laboratories announced today that it enrolled the first patient in the trial for its Revita DMR Type 2 diabetes treatment. The Revita-T2Di trial will evaluate a single Revita DMR treatment to allow patients currently on insulin therapy but with inadequate glycemic control to achieve durable insulin-free glycemic control. The company will seek to use […]

Filed Under: Clinical Trials, Diabetes, Featured Tagged With: fractyllaboratories

BioCorp, Diabeloop partner on diabetes management tech development

March 22, 2021 By Sean Whooley

Biocorp Diabeloop

BioCorp and Diabeloop announced today that they are entering a cooperation agreement to develop new personalized diabetes treatments. Diabeloop develops automated insulin delivery (AID) systems, including a self-learning algorithm hosted in a handset and connected to a continuous glucose monitoring (CGM) system and an insulin pump. The platform analyzes glucose data, calculates the right dose […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: biocorp, Diabeloop

Insulet touts results from Omnipod 5 study, expects launch this year

March 22, 2021 By Sean Whooley

Insulet

Insulet (NSDQ:PODD) touted positive results from the first pivotal trial for its Omnipod 5 automated insulin delivery system. Omnipod 5 is the world’s first tubeless, wearable system designed to continuously adapt insulin delivery based on glucose levels and trends, according to a news release. Acton, Mass.-based Insulet said the device, which has FDA breakthrough device […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Insulet

FDA approves oral multiple sclerosis treatment from J&J’s Janssen unit

March 19, 2021 By Sean Whooley

Updated Janssen logo

Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical announced today that it received FDA approval for its Ponvory treatment. Ponvory (ponesimod) is a once-daily, oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator for treating adults with relapsing forms of multiple sclerosis (MS). It’s areas of treatment include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals Tagged With: Janssen Pharmaceuticals, Johnson & Johnson

Oramed forms joint venture to develop oral COVID-19 vaccines with POD delivery tech

March 19, 2021 By Sean Whooley

Oramed

Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it is forming a joint venture to develop novel oral COVID-19 vaccines. New York-based Oramed entered into definitive agreements to form Oravax Medical, which is based on Oramed’s proprietary POD (protein oral delivery) technology and Premas Biotech’s novel vaccine technology, according to a news release. Oravax’s COVID-19 vaccine candidate […]

Filed Under: Business/Financial News, Discovery, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: coronavirus, COVID-19, COVID-19 vaccine, oramedpharmaceuticals

How Lyra Therapeutics is advancing rhinosinusitis treatment

March 19, 2021 By Sean Whooley

Lyra Therapeutics LYR-210

With the use of anti-inflammatory drugs constituting the standard of care for treating rhinosinusitis, Lyra Therapeutics sees an opportunity. Whatever treatments are out there for the disease in which cavities around the nasal passages are inflamed, they leave room for improvement. “We focused on chronic rhinosinusitis because it’s an area that has been ignored,” Lyra […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Respiratory Tagged With: Lyra Therapeutics

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 150
  • Page 151
  • Page 152
  • Page 153
  • Page 154
  • Interim pages omitted …
  • Page 174
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS